{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:13:25Z","timestamp":1791252805547,"version":"4.1.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["GR-2018-12368387"],"award-info":[{"award-number":["GR-2018-12368387"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002803","name":"Fondazione Cariplo","doi-asserted-by":"publisher","award":["#2018-0257"],"award-info":[{"award-number":["#2018-0257"]}],"id":[{"id":"10.13039\/501100002803","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["Accelerator Award Program"],"award-info":[{"award-number":["Accelerator Award Program"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["Accelerator Award Program"],"award-info":[{"award-number":["Accelerator Award Program"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004769","name":"Universit\u00e0 degli Studi di Pavia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004769","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40259-022-00550-w","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T13:06:53Z","timestamp":1662988013000},"page":"591-608","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8334-1684","authenticated-orcid":false,"given":"Mario","family":"Nuvolone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7724-1043","authenticated-orcid":false,"given":"Alice","family":"Nevone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7680-3254","authenticated-orcid":false,"given":"Giampaolo","family":"Merlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"issue":"6","key":"550_CR1","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583\u201396. https:\/\/doi.org\/10.1056\/NEJMra023144.","journal-title":"N Engl J Med"},{"issue":"1","key":"550_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","volume":"4","author":"G Merlini","year":"2018","unstructured":"Merlini G, Dispenzieri A, Sanchorawala V, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4(1):38. https:\/\/doi.org\/10.1038\/s41572-018-0034-3.","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"550_CR3","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1073\/pnas.0912263107","volume":"107","author":"J Shi","year":"2010","unstructured":"Shi J, Guan J, Jiang B, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A. 2010;107(9):4188\u201393. https:\/\/doi.org\/10.1073\/pnas.0912263107.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"550_CR4","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.1096\/fj.15-272179","volume":"29","author":"F Lavatelli","year":"2015","unstructured":"Lavatelli F, Imperlini E, Orru S, et al. Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis. FASEB J. 2015;29(11):4614\u201328. https:\/\/doi.org\/10.1096\/fj.15-272179.","journal-title":"FASEB J"},{"issue":"8","key":"550_CR5","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1161\/01.RES.0000126569.75419.74","volume":"94","author":"DA Brenner","year":"2004","unstructured":"Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 2004;94(8):1008\u201310.","journal-title":"Circ Res"},{"issue":"38","key":"550_CR6","doi-asserted-by":"publisher","first-page":"19813-25","DOI":"10.1074\/jbc.M116.736736","volume":"291","author":"M Marin-Argany","year":"2016","unstructured":"Marin-Argany M, Lin Y, Misra P, et al. Cell damage in light chain amyloidosis: fibril internalization, toxicity and cell-mediated seeding. J Biol Chem. 2016;291(38):19813\u201325. https:\/\/doi.org\/10.1074\/jbc.M116.736736.","journal-title":"J Biol Chem"},{"key":"550_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev.med.57.121304.131243","volume":"57","author":"MB Pepys","year":"2006","unstructured":"Pepys MB. Amyloidosis. Annu Rev Med. 2006;57:223\u201341. https:\/\/doi.org\/10.1146\/annurev.med.57.121304.131243.","journal-title":"Annu Rev Med"},{"issue":"9","key":"550_CR8","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1073\/pnas.0400062101","volume":"101","author":"N Reixach","year":"2004","unstructured":"Reixach N, Deechongkit S, Jiang X, et al. Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci U S A. 2004;101(9):2817\u201322. https:\/\/doi.org\/10.1073\/pnas.0400062101.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"31","key":"550_CR9","doi-asserted-by":"publisher","first-page":"21998","DOI":"10.1074\/jbc.M602302200","volume":"281","author":"PF Teixeira","year":"2006","unstructured":"Teixeira PF, Cerca F, Santos SD, et al. Endoplasmic reticulum stress associated with extracellular aggregates. Evidence from transthyretin deposition in familial amyloid polyneuropathy. J Biol Chem. 2006;281(31):21998\u20132003. https:\/\/doi.org\/10.1074\/jbc.M602302200.","journal-title":"J Biol Chem"},{"issue":"2","key":"550_CR10","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1148\/radiol.2015141744","volume":"277","author":"M Fontana","year":"2015","unstructured":"Fontana M, Banypersad SM, Treibel TA, et al. Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: a cardiac MR imaging study. Radiology. 2015;277(2):388\u201397. https:\/\/doi.org\/10.1148\/radiol.2015141744.","journal-title":"Radiology"},{"issue":"19","key":"550_CR11","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1182\/blood.2020008737","volume":"139","author":"G Palladini","year":"2022","unstructured":"Palladini G, Merlini G. How I treat AL amyloidosis. Blood. 2022;139(19):2918\u201330. https:\/\/doi.org\/10.1182\/blood.2020008737.","journal-title":"Blood"},{"issue":"1","key":"550_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/asheducation-2017.1.1","volume":"2017","author":"G Merlini","year":"2017","unstructured":"Merlini G. AL amyloidosis: from molecular mechanisms to targeted therapies. Hematol Am Soc Hematol Educ Program. 2017;2017(1):1\u201312. https:\/\/doi.org\/10.1182\/asheducation-2017.1.1.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"7","key":"550_CR13","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s11864-021-00922-4","volume":"23","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Comenzo RL. Immunotherapy in AL amyloidosis. Curr Treat Options Oncol. 2022;23(7):1059\u201371. https:\/\/doi.org\/10.1007\/s11864-021-00922-4.","journal-title":"Curr Treat Options Oncol"},{"key":"550_CR14","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.3389\/fphar.2020.01024","volume":"11","author":"A Nevone","year":"2020","unstructured":"Nevone A, Merlini G, Nuvolone M. Treating protein misfolding diseases: therapeutic successes against systemic amyloidoses. Front Pharmacol. 2020;11:1024. https:\/\/doi.org\/10.3389\/fphar.2020.01024.","journal-title":"Front Pharmacol"},{"issue":"4","key":"550_CR15","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jaccao.2021.06.006","volume":"3","author":"JM Griffin","year":"2021","unstructured":"Griffin JM, Rosenthal JL, Grodin JL, et al. ATTR amyloidosis: current and emerging management strategies: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2021;3(4):488\u2013505. https:\/\/doi.org\/10.1016\/j.jaccao.2021.06.006.","journal-title":"JACC CardioOncol."},{"issue":"7","key":"550_CR16","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1073\/pnas.92.7.2959","volume":"92","author":"G Merlini","year":"1995","unstructured":"Merlini G, Ascari E, Amboldi N, et al. Interaction of the anthracycline 4\u2019-iodo-4\u2019-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci U S A. 1995;92(7):2959\u201363.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"550_CR17","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/S0002-9440(10)65065-1","volume":"156","author":"JA Palha","year":"2000","unstructured":"Palha JA, Ballinari D, Amboldi N, et al. 4 \u2019-iodo-4 \u2019-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid. Am J Pathol. 2000;156(6):1919\u201325.","journal-title":"Am J Pathol"},{"issue":"18","key":"550_CR18","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","volume":"22","author":"A Dispenzieri","year":"2004","unstructured":"Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751\u20137.","journal-title":"J Clin Oncol"},{"issue":"21","key":"550_CR19","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1182\/blood.V118.21.995.995","volume":"118","author":"A Wechalekar","year":"2011","unstructured":"Wechalekar A, Schonland SO, Kastritis E, et al. European Collaborative study of treatment outcomes in 347 patients with systemic AL amyloidosis with mayo stage III disease. Blood. 2011;118(21):454\u20135.","journal-title":"Blood"},{"issue":"1","key":"550_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jacc.2016.04.035","volume":"68","author":"AV Kristen","year":"2016","unstructured":"Kristen AV, Brokbals E, Aus dem Siepen F, et al. Cardiac amyloid load: a prognostic and predictive biomarker in patients with light-chain amyloidosis. J Am Coll Cardiol. 2016;68(1):13\u201324. https:\/\/doi.org\/10.1016\/j.jacc.2016.04.035.","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"550_CR21","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541\u20139. https:\/\/doi.org\/10.1200\/JCO.2011.37.7614.","journal-title":"J Clin Oncol"},{"issue":"6","key":"550_CR22","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.009038","volume":"15","author":"MS Maurer","year":"2022","unstructured":"Maurer MS, Dunnmon P, Fontana M, et al. Proposed cardiac end points for clinical trials in immunoglobulin light chain amyloidosis: report from the Amyloidosis Forum Cardiac Working Group. Circ Heart Fail. 2022;15(6): e009038. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.121.009038.","journal-title":"Circ Heart Fail"},{"key":"550_CR23","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2022.2052838","author":"Y Ando","year":"2022","unstructured":"Ando Y. Guidelines and New directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid. 2022. https:\/\/doi.org\/10.1080\/13506129.2022.2052838.","journal-title":"Amyloid"},{"issue":"10","key":"550_CR24","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","volume":"128","author":"JM Griffin","year":"2021","unstructured":"Griffin JM, Rosenblum H, Maurer MS. Pathophysiology and therapeutic approaches to cardiac amyloidosis. Circ Res. 2021;128(10):1554\u201375. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318187.","journal-title":"Circ Res"},{"issue":"6","key":"550_CR25","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ejhf.2198","volume":"23","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Bengel F, Brito D, et al. Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2021;23(6):895\u2013905. https:\/\/doi.org\/10.1002\/ejhf.2198.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"550_CR26","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000479240","volume":"44","author":"A Kretschmer","year":"2017","unstructured":"Kretschmer A, Schwanbeck R, Valerius T, et al. Antibody Isotypes for Tumor Immunotherapy. Transfus Med Hemother. 2017;44(5):320\u20136. https:\/\/doi.org\/10.1159\/000479240.","journal-title":"Transfus Med Hemother."},{"issue":"2","key":"550_CR27","first-page":"284","volume":"38","author":"MB Pepys","year":"1979","unstructured":"Pepys MB, Dyck RF, de Beer FC, et al. Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol. 1979;38(2):284\u201393.","journal-title":"Clin Exp Immunol"},{"issue":"6886","key":"550_CR28","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/417254a","volume":"417","author":"MB Pepys","year":"2002","unstructured":"Pepys MB, Herbert J, Hutchinson WL, et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature. 2002;417(6886):254\u20139. https:\/\/doi.org\/10.1038\/417254a.","journal-title":"Nature"},{"issue":"5","key":"550_CR29","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/j.1365-2141.2009.08036.x","volume":"148","author":"JD Gillmore","year":"2010","unstructured":"Gillmore JD, Tennent GA, Hutchinson WL, et al. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol. 2010;148(5):760\u20137. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.08036.x.","journal-title":"Br J Haematol"},{"issue":"5","key":"550_CR30","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/cpdd.631","volume":"8","author":"H Ino","year":"2019","unstructured":"Ino H, Doi Y, Liefaard L, et al. Evaluation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single intravenous dose of miridesap in healthy Japanese subjects. Clin Pharmacol Drug Dev. 2019;8(5):612\u20138. https:\/\/doi.org\/10.1002\/cpdd.631.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"7320","key":"550_CR31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nature09494","volume":"468","author":"K Bodin","year":"2010","unstructured":"Bodin K, Ellmerich S, Kahan MC, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature. 2010;468(7320):93\u20137. https:\/\/doi.org\/10.1038\/nature09494.","journal-title":"Nature"},{"issue":"12","key":"550_CR32","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","volume":"373","author":"DB Richards","year":"2015","unstructured":"Richards DB, Cookson LM, Berges AC, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med. 2015;373(12):1106\u201314. https:\/\/doi.org\/10.1056\/NEJMoa1504942.","journal-title":"N Engl J Med"},{"issue":"422","key":"550_CR33","doi-asserted-by":"publisher","first-page":"eaan3128","DOI":"10.1126\/scitranslmed.aan3128","volume":"10","author":"DB Richards","year":"2018","unstructured":"Richards DB, Cookson LM, Barton SV, et al. Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis. Sci Transl Med. 2018;10(422):eaan3128. https:\/\/doi.org\/10.1126\/scitranslmed.aan3128.","journal-title":"Sci Transl Med."},{"issue":"1","key":"550_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12872-021-02407-6","volume":"22","author":"A Wechalekar","year":"2022","unstructured":"Wechalekar A, Antoni G, Al Azzam W, et al. Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study. BMC Cardiovasc Disord. 2022;22(1):49. https:\/\/doi.org\/10.1186\/s12872-021-02407-6.","journal-title":"BMC Cardiovasc Disord"},{"key":"550_CR35","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.3389\/fimmu.2020.01951","volume":"11","author":"A Vaisman-Mentesh","year":"2020","unstructured":"Vaisman-Mentesh A, Gutierrez-Gonzalez M, DeKosky BJ, et al. The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies. Front Immunol. 2020;11:1951. https:\/\/doi.org\/10.3389\/fimmu.2020.01951.","journal-title":"Front Immunol"},{"issue":"11","key":"550_CR36","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.it.2007.07.011","volume":"28","author":"AS De Groot","year":"2007","unstructured":"De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol. 2007;28(11):482\u201390. https:\/\/doi.org\/10.1016\/j.it.2007.07.011.","journal-title":"Trends Immunol"},{"issue":"4","key":"550_CR37","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrd3003","volume":"9","author":"TT Hansel","year":"2010","unstructured":"Hansel TT, Kropshofer H, Singer T, et al. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9(4):325\u201338. https:\/\/doi.org\/10.1038\/nrd3003.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"550_CR38","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1365-2133.1981.tb01195.x","volume":"105","author":"SM Breathnach","year":"1981","unstructured":"Breathnach SM, Bhogal B, Dyck RF, et al. Immunohistochemical demonstration of amyloid P component in skin of normal subjects and patients with cutaneous amyloidosis. Br J Dermatol. 1981;105(2):115\u201324. https:\/\/doi.org\/10.1111\/j.1365-2133.1981.tb01195.x.","journal-title":"Br J Dermatol"},{"issue":"5","key":"550_CR39","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1084\/jem.152.5.1162","volume":"152","author":"RF Dyck","year":"1980","unstructured":"Dyck RF, Lockwood CM, Kershaw M, et al. Amyloid P-component is a constituent of normal human glomerular basement membrane. J Exp Med. 1980;152(5):1162\u201374. https:\/\/doi.org\/10.1084\/jem.152.5.1162.","journal-title":"J Exp Med"},{"issue":"3","key":"550_CR40","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/BF00163818","volume":"25","author":"H al-Mutlaq","year":"1993","unstructured":"al-Mutlaq H, Wheeler J, Robertson H, et al. Tissue distribution of amyloid P component as defined by a monoclonal antibody produced by immunization with human glomerular basement membranes. Histochem J. 1993;25(3):219\u201327. https:\/\/doi.org\/10.1007\/BF00163818.","journal-title":"Histochem J"},{"issue":"Suppl","key":"550_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2020-143307","volume":"136","author":"JS Wall","year":"2020","unstructured":"Wall JS, Heidel RE, Stuckey A, et al. Detection of systemic AL amyloidosis and differentiation of AL from Attr using I-124-p5+14 PET imaging. Blood. 2020;136(Suppl):1. https:\/\/doi.org\/10.1182\/blood-2020-143307.","journal-title":"Blood"},{"key":"550_CR42","unstructured":"Attralus [cited 7 May 2022]. https:\/\/attralus.com\/pipeline. Accessed 15 May 2022."},{"key":"550_CR43","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1182\/blood-2021-151908","volume":"138","author":"C Sirac","year":"2021","unstructured":"Sirac C, Jaccard A, Codo R, et al. Pre-clinical characterization of a novel fusion protein (AT-03), with pan-amyloid binding and removal. Blood. 2021;138:1207.","journal-title":"Blood"},{"key":"550_CR44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3389\/fimmu.2011.00032","volume":"2","author":"JS Wall","year":"2011","unstructured":"Wall JS, Kennel SJ, Richey T, et al. Generation and characterization of anti-AA amyloid-specific monoclonal antibodies. Front Immunol. 2011;2:32. https:\/\/doi.org\/10.3389\/fimmu.2011.00032.","journal-title":"Front Immunol"},{"issue":"12","key":"550_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052686","volume":"7","author":"JS Wall","year":"2012","unstructured":"Wall JS, Kennel SJ, Williams A, et al. AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PLoS ONE. 2012;7(12): e52686. https:\/\/doi.org\/10.1371\/journal.pone.0052686.","journal-title":"PLoS ONE"},{"issue":"3","key":"550_CR46","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1080\/13506129.2016.1205974","volume":"23","author":"M Renz","year":"2016","unstructured":"Renz M, Torres R, Dolan PJ, et al. 2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis dagger. Amyloid. 2016;23(3):168\u201377. https:\/\/doi.org\/10.1080\/13506129.2016.1205974.","journal-title":"Amyloid"},{"issue":"10","key":"550_CR47","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","volume":"34","author":"MA Gertz","year":"2016","unstructured":"Gertz MA, Landau H, Comenzo RL, et al. First-in-human phase I\/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol. 2016;34(10):1097\u2013103. https:\/\/doi.org\/10.1200\/JCO.2015.63.6530.","journal-title":"J Clin Oncol"},{"key":"550_CR48","unstructured":"ClinicalTrials.gov. The PRONTO study, a global phase 2B study of NEOD001 in previously treated subjects with light chain (AL) amyloidosis (PRONTO). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02632786."},{"key":"550_CR49","unstructured":"ClinicalTrials.gov. The VITAL amyloidosis study, a global phase 3, efficacy and safety study of NEOD001 in patients with AL amyloidosis (VITAL). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02312206."},{"issue":"9","key":"550_CR50","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989\u201395. https:\/\/doi.org\/10.1200\/JCO.2011.38.5724.","journal-title":"J Clin Oncol"},{"key":"550_CR51","unstructured":"ClinicalTrials.gov. A study to evaluate the efficacy and safety of Birtamimab in Mayo stage IV patients with AL amyloidosis (AFFIRM-AL). https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04973137."},{"issue":"Suppl 16","key":"550_CR52","doi-asserted-by":"publisher","first-page":"abstract no. TP","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8076","volume":"40","author":"MA Gertz","year":"2022","unstructured":"Gertz MA, Sanchorawala V, Wechalekar A, et al. Birtamimab in patients with Mayo stage IV AL amyloidosis: rationale for confirmatory affirm-AL phase 3 study. 2022 ASCO Annual Meeting. J Clin Oncol. 2022;40(Suppl 16):abstract no. TPS8076.","journal-title":"J Clin Oncol"},{"issue":"10","key":"550_CR53","first-page":"3831S","volume":"9","author":"A Solomon","year":"2003","unstructured":"Solomon A, Weiss DT, Wall JS. Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11\u20131F4. Clin Cancer Res. 2003;9(10):3831S-3838S.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"550_CR54","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S0002-9440(10)64639-1","volume":"157","author":"R Hrncic","year":"2000","unstructured":"Hrncic R, Wall J, Wolfenbarger DA, et al. Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol. 2000;157(4):1239\u201346.","journal-title":"Am J Pathol"},{"issue":"5","key":"550_CR55","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1021\/bi0616605","volume":"46","author":"B O'Nuallain","year":"2007","unstructured":"O\u2019Nuallain B, Allen A, Kennel SJ, et al. Localization of a conformational epitope common to non-native and fibrillar immunoglobulin light chains. Biochemistry. 2007;46(5):1240\u20137.","journal-title":"Biochemistry"},{"issue":"13","key":"550_CR56","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1182\/blood-2010-03-273797","volume":"116","author":"JS Wall","year":"2010","unstructured":"Wall JS, Kennel SJ, Stuckey AC, et al. Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood. 2010;116(13):2241\u20134. https:\/\/doi.org\/10.1182\/blood-2010-03-273797.","journal-title":"Blood"},{"issue":"25","key":"550_CR57","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1182\/blood.2020009039","volume":"138","author":"CV Edwards","year":"2021","unstructured":"Edwards CV, Rao N, Bhutani D, et al. Phase 1a\/b study of monoclonal antibody CAEL-101 (11\u20131F4) in patients with AL amyloidosis. Blood. 2021;138(25):2632\u201341. https:\/\/doi.org\/10.1182\/blood.2020009039.","journal-title":"Blood"},{"issue":"48","key":"550_CR58","doi-asserted-by":"publisher","first-page":"25096","DOI":"10.1074\/jbc.M116.738138","volume":"291","author":"A Hosoi","year":"2016","unstructured":"Hosoi A, Su Y, Torikai M, et al. Novel antibody for the treatment of transthyretin amyloidosis. J Biol Chem. 2016;291(48):25096\u2013105. https:\/\/doi.org\/10.1074\/jbc.M116.738138.","journal-title":"J Biol Chem"},{"issue":"1","key":"550_CR59","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1038\/s41467-021-23274-x","volume":"12","author":"A Michalon","year":"2021","unstructured":"Michalon A, Hagenbuch A, Huy C, et al. A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells. Nat Commun. 2021;12(1):3142. https:\/\/doi.org\/10.1038\/s41467-021-23274-x.","journal-title":"Nat Commun"},{"issue":"2","key":"550_CR60","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/13506129.2016.1148025","volume":"23","author":"JN Higaki","year":"2016","unstructured":"Higaki JN, Chakrabartty A, Galant NJ, et al. Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin. Amyloid. 2016;23(2):86\u201397. https:\/\/doi.org\/10.3109\/13506129.2016.1148025.","journal-title":"Amyloid"},{"issue":"22","key":"550_CR61","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1212\/wnl.0000000000012044","volume":"96","author":"O Suhr","year":"2021","unstructured":"Suhr O, Grogan M, Martins de Silva A, et al. Neurological and cardiac improvements with PRX004 in amyloidosis patients: results of a phase 1 study, 2021 Emerging Science Abstracts. 2021 AAN Annual meeting abstracts. Neurology. 2021;96(22):2783\u20138. https:\/\/doi.org\/10.1212\/wnl.0000000000012044.","journal-title":"Neurology"},{"key":"550_CR62","unstructured":"Novo Nordisk. Prothena and Novo Nordisk accounce acquisition agreement for Prothena\u2019s ATTR amyloidosis programme. https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news-and-media\/news-and-ir-materials\/news-details.html?id=67562 . Accessed 15 May 2022."},{"issue":"Suppl 1","key":"550_CR63","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1182\/blood-2021-149222","volume":"138","author":"E Muchtar","year":"2021","unstructured":"Muchtar E, Dispenzieri A, Wisniowski B, et al. Graded cardiac response criteria for AL amyloidosis: the impact of depth of cardiac response on survival. Blood. 2021;138(Suppl 1):2720\u20132720. https:\/\/doi.org\/10.1182\/blood-2021-149222.","journal-title":"Blood"},{"issue":"1","key":"550_CR64","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/s41467-019-09133-w","volume":"10","author":"P Swuec","year":"2019","unstructured":"Swuec P, Lavatelli F, Tasaki M, et al. Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient. Nat Commun. 2019;10(1):1269. https:\/\/doi.org\/10.1038\/s41467-019-09133-w.","journal-title":"Nat Commun"},{"issue":"1","key":"550_CR65","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41467-019-09032-0","volume":"10","author":"L Radamaker","year":"2019","unstructured":"Radamaker L, Lin YH, Annamalai K, et al. Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis. Nat Commun. 2019;10(1):1103. https:\/\/doi.org\/10.1038\/s41467-019-09032-0.","journal-title":"Nat Commun"},{"issue":"1","key":"550_CR66","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.1038\/s41467-019-13038-z","volume":"10","author":"M Schmidt","year":"2019","unstructured":"Schmidt M, Wiese S, Adak V, et al. Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis. Nat Commun. 2019;10(1):5008. https:\/\/doi.org\/10.1038\/s41467-019-13038-z.","journal-title":"Nat Commun"},{"issue":"6483","key":"550_CR67","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1126\/science.aaz9356","volume":"367","author":"L Rouge","year":"2020","unstructured":"Rouge L, Chiang N, Steffek M, et al. Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab. Science. 2020;367(6483):1224\u201330. https:\/\/doi.org\/10.1126\/science.aaz9356.","journal-title":"Science"},{"key":"550_CR68","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ddtec.2020.12.003","volume":"38","author":"C Wigge","year":"2020","unstructured":"Wigge C, Stefanovic A, Radjainia M. The rapidly evolving role of cryo-EM in drug design. Drug Discov Today Technol. 2020;38:91\u2013102. https:\/\/doi.org\/10.1016\/j.ddtec.2020.12.003.","journal-title":"Drug Discov Today Technol"},{"issue":"10","key":"550_CR69","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/leu.2016.191","volume":"30","author":"G Merlini","year":"2016","unstructured":"Merlini G, Lousada I, Ando Y, et al. Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia. 2016;30(10):1979\u201386. https:\/\/doi.org\/10.1038\/leu.2016.191.","journal-title":"Leukemia"},{"key":"550_CR70","doi-asserted-by":"publisher","unstructured":"Maurer MS, Dunnmon P, Fontana M, Quarta CC, Prasad K, Witteles RM, et al. Proposed cardiac end points for clinical trials in immunoglobulin light chain amyloidosis: report from the amyloidosis forum cardiac working group. Circ Heart Fail. 2022;15(6):e009038. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.121.009038.","DOI":"10.1161\/CIRCHEARTFAILURE.121.009038"},{"issue":"7886","key":"550_CR71","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/d41586-021-03410-9","volume":"599","author":"A Mullard","year":"2021","unstructured":"Mullard A. More Alzheimer\u2019s drugs head for FDA review: what scientists are watching. Nature. 2021;599(7886):544\u20135. https:\/\/doi.org\/10.1038\/d41586-021-03410-9.","journal-title":"Nature"},{"issue":"10149","key":"550_CR72","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S0140-6736(18)31069-9","volume":"392","author":"L Luzzatto","year":"2018","unstructured":"Luzzatto L, Hyry HI, Schieppati A, et al. Outrageous prices of orphan drugs: a call for collaboration. Lancet. 2018;392(10149):791\u20134. https:\/\/doi.org\/10.1016\/S0140-6736(18)31069-9.","journal-title":"Lancet"},{"issue":"5","key":"550_CR73","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000477","volume":"4","author":"G Merlini","year":"2020","unstructured":"Merlini G, Gribben J, Macintyre E, et al. Access to affordable orphan medicines in europe: an EHA Position Paper. Hemasphere. 2020;4(5): e477. https:\/\/doi.org\/10.1097\/HS9.0000000000000477.","journal-title":"Hemasphere."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00550-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-022-00550-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00550-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T16:10:19Z","timestamp":1668183019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-022-00550-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":73,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["550"],"URL":"https:\/\/doi.org\/10.1007\/s40259-022-00550-w","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"7 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 degli Studi di Pavia within the CRUI-CARE Agreement. This work was supported by grants from the Italian Ministry of Health (Ricerca Finalizzata, Grant number GR-2018-12368387) [to MN], CARIPLO Foundation (Grant #2018-0257) [to MN], Cancer Research UK [C355\/A26819], FC AECC and AIRC under the Accelerator Award Program [to MN, GM].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/publish"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Mario Nuvolone is an inventor on a patent application unrelated to this work, and received research funding from Oncopeptides and Gate Bioscience. Alice Nevone declares no conflicts of interest. Giampaolo Merlini is a member of the Advisory Board of Janssen and Pfizer.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"GM conceived the study and drafted the initial version of the manuscript. All authors contributed to the literature research, data analysis, and writing. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}